Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise & Strong Commercial Leadership ...
May 22 2017 - 9:00AM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) announced today that Mark Van
Oene has been named Chief Commercial Officer. Van Oene was
previously Illumina’s Senior Vice President of the Americas region
and subsequently named interim Chief Commercial Officer in late
2016.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170522005470/en/
Illumina Chief Commercial Officer Mark
Van Oene (Photo: Business Wire)
“Mark is a great leader for our commercial organization,
possessing deep genomics expertise and over a decade of experience
building and running strong sales and marketing teams,” said
Francis deSouza, Illumina President and Chief Executive Officer.
“As interim Chief Commercial Officer Mark has guided Illumina
through two strong quarters, including the launch of NovaSeq, and
laid the foundation for our future growth. I am excited to continue
to work closely with Mark to expand our commercial capability as we
grow in research and clinical markets around the world.”
Van Oene joined Illumina in 2006 as Regional Account Manager for
Canada. In 2008, Van Oene was promoted to Senior Director of Sales
for the Americas. Four years later, he was promoted to Vice
President with responsibility for global sales. From 2012 through
2014, Van Oene led the team to grow revenues from $1.06B to $1.42B.
In early 2014, Van Oene was named the General Manager for the
Americas region, advancing to Senior Vice President in April 2016.
During that time, the Americas compound annual growth rate exceeded
20%.
As Chief Commercial Officer, Van Oene will be responsible for
world-wide sales, services and marketing at Illumina. He will
report to President and CEO, Francis deSouza.
Van Oene earned a Bachelor of Science degree in Biochemistry
from Western University in London, Ontario, Canada.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical and applied markets.
Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture, and other emerging
segments. To learn more, visit www.illumina.com and
follow @illumina.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170522005470/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243IR@illumina.comorMedia:Eric Endicott,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024